Skip to main content
LYEL
NASDAQ Life Sciences

ARCH Venture Fund IX Makes Significant $12.5M Open Market Purchase in Lyell Immunopharma

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$26.3
Mkt Cap
$541.721M
52W Low
$7.65
52W High
$45
52W Position info
244% above low
Off High info
42% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

LYEL has more than doubled off its 52-week low of $7.65 on elevated volume (2.1× avg).

Summary

ARCH Venture Fund IX, a 10% owner, reported an open market purchase of Lyell Immunopharma shares totaling nearly $12.5 million, signaling strong conviction.


Key Events · Ownership and Investor Activity · LYEL

  • Significant Insider Purchase

    ARCH Venture Fund IX, a 10% owner, acquired 488,090 shares of Lyell Immunopharma common stock in an open market transaction.

  • Substantial Investment Value

    The total value of the purchase was approximately $12.5 million, executed at a price of $25.61 per share on March 6, 2026.

  • Context of Recent Financing

    This purchase follows news of Lyell Immunopharma closing a $50 million tranche of an equity private placement, suggesting ARCH's participation in the broader capital raise.


Analysis · LYEL · Life Sciences

This substantial open market purchase by ARCH Venture Fund IX, a major 10% owner, represents a significant vote of confidence in Lyell Immunopharma. The $12.5 million investment, occurring on March 6th, likely relates to the recently announced closing of a $50 million equity private placement tranche. Such a large investment from a venture fund, especially following other financing news, suggests a positive outlook on the company's future prospects and capital position.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LYEL was trading at $26.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $541.7M. The 52-week trading range was $7.65 to $45.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LYEL - Latest Insights

LYEL
Nov 04, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.74
Real-time Price: $13.80 info
Change: -$0.940 (-6%) info
Market Cap: $339.281M info
LYEL
Nov 04, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.33
Real-time Price: $13.80 info
Change: -$1.53 (-10%) info
Market Cap: $339.281M info
LYEL
Nov 04, 2026, 9:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.76
Real-time Price: $13.80 info
Change: +$2.04 (+17%) info
Market Cap: $339.281M info
LYEL
Nov 04, 2026, 9:02 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.77
Real-time Price: $13.80 info
Change: +$3.03 (+28%) info
Market Cap: $339.281M info
LYEL
Nov 04, 2026, 9:01 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.76
Real-time Price: $13.80 info
Change: +$2.04 (+17%) info
Market Cap: $339.281M info